

Mikron Holding

H126 results

On track to hit FY26 targets

Mikron reported H126 results that confirmed a slowdown in revenue after a record H125 performance. Despite the lower revenue, the operating margin remained within the range expected for FY26. While the Automation business saw slower revenue and order intake as pharma customers digested recent purchases, the Tool business saw strong growth and the Machining business appears to be approaching the bottom for order intake. The company reiterated its outlook for FY26 and we maintain our forecasts.

Year end	Revenue (CHFm)	PBT (CHFm)	EPS (CHF)	DPS (CHF)	P/E (x)	Yield (%)
12/24	374.1	31.7	1.72	0.50	9.4	3.1
12/25	381.9	37.9	1.96	0.60	8.2	3.7
12/26e	359.2	29.3	1.49	0.50	10.8	3.1
12/27e	372.1	31.9	1.62	0.54	9.9	3.4

Note: PBT and diluted EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

H126 revenue CHF180.5m, operating margin 8.9%

In H126 Mikron reported a revenue decline of 5.9% y-o-y (3.5% in constant currency) to CHF180.5m. Automation declined 8.0% y-o-y, Machining declined 13.4% and Tool grew 12.6%. Operating profit declined 25.5% to CHF16.1m and the operating margin was down 2.3pp to 8.9%. Order intake declined 39.1% y-o-y to CHF134.5m (book-to-bill 0.75x), with Automation down 54.0%, Machining down 0.9% and Tool up 17.6%. Net cash at end-H126 was flat versus end-FY25 at CHF98m.

Expanding global footprint

Various investments are underway to support growth globally, including a new Tool facility in the US and a new legal entity being set up in India to support activities across all three divisions in the region. The Boudry Next capacity expansion project is progressing well and should be complete by year-end; this should benefit operating margins from FY27. Cost reduction measures have been implemented, benefiting FY26 margins. This is in addition to the longer-term operational excellence programme, which should support higher operating margins from FY27. Management maintained its guidance for FY26: revenue of CHF340–380m and an operating margin in the range 7–10%. We maintain our forecasts, which are within the ranges.

Valuation: Modest growth presents upside

On a P/E basis, the stock trades at a significant discount to Swiss industrial machinery companies and its main US peer, partly due to lower-than-average revenue growth and margins. Our discounted cash flow analysis (assumptions: WACC 7.5%, long-term growth 2%, revenue growth of 3% per year and average operating margins of 8.5% from FY28–35) calculates a value of CHF23.6/share, 47% above the current share price. If we factor in the target growth rate of 5% per year and average margins of 9.5% (mid-point of the target range), the valuation increases to CHF29.8/share. We view returning to order growth as the near-term trigger to reduce the discount.


General industrials

20 July 2026

Price CHF16.10
Market cap CHF269m

Net cash/(debt) at end H126 CHF98.2m
Shares in issue 16.7m
Free float 45.0%
Code MIKN
Primary exchange SWX
Secondary exchange N/A

Share price performance



Business description

Mikron Holding (Mikron) develops, produces and markets highly precise, productive and adaptable automation solutions and machining solutions.

Analyst

Katherine Thompson +44 (0)20 3077 5700

industrials@edisongroup.com

[Edison profile page](#)

Mikron Holding is a research client of Edison Investment Research Limited

Review of H126 results

The company reported H126 revenue of CHF180.5m, down 5.9% y-o-y or 3.5% in constant currency. This resulted in a decline in operating profit of 25.5% y-o-y. The operating margin declined 2.3pp to 8.9% but was within management's 7–10% FY26 guidance range. Net income of CHF13.8m was 24% lower year-on-year, after tax of CHF1.9m (11.9% rate).

Group order intake fell 39% and the order backlog declined 34%, with a group book-to-bill of 0.75x. We discuss divisional performance below. For the first time, the company has split the performance of Machine Solutions into Machining and Tool.

Operating cash flow of CHF17.0m was offset by capex of CHF7.1m and payment of the dividend (CHF9.9m). The company noted that investment in its Boudry expansion project made up CHF3.9m of capex in H126 and will cost a further CHF3.2m in H226, when the project should complete. The group continues to maintain a strong net cash position of €98.2m at the end of H126.

Exhibit 1: H126 results highlights

CHFm	H126	H125	y-o-y
<u>Order intake</u>			
Automation	77.6	168.8	-54.0%
Machining	23.1	23.3	-0.9%
Tool	34.0	28.9	17.6%
Total	134.5	220.7	-39.1%
<u>Order backlog</u>			
Automation	175.9	274.0	-35.8%
Machining	49.1	73.2	-32.9%
Tool	7.4	4.9	51.0%
Total	232.3	351.9	-34.0%
<u>Net sales</u>			
Automation	115.6	125.7	-8.0%
Machining	32.1	37.1	-13.4%
Tool	33.0	29.3	12.6%
Total	180.5	191.9	-5.9%
<u>Book-to-bill (x)</u>			
Automation	0.67	1.34	
Machining	0.72	0.63	
Tool	1.03	0.99	
Total	0.75	1.15	
Operating profit	16.1	21.6	-25.5%
Operating margin	8.9%	11.3%	-2.3pp
Profit before tax	15.7	20.6	-23.6%
Net income	13.8	18.3	-24.2%
Basic EPS (CHF)	0.83	1.10	-24.5%
Net cash	98.2	103.0	-4.7%

Source: Mikron

Mikron Automation

Revenue normalised after an exceptionally strong performance in H125 and was 8.0% lower year-on-year. Pharma/Medtech continued to generate 97% of revenue. Revenue by geography shifted, from 66% in Europe in H125 to 52% in H126. Revenue from North America increased from 15% to 17% y-o-y and Asia-Pacific from 8% to 18%. Order intake declined 54% y-o-y, reflecting weakness in Europe, but was 22% higher half-on-half. Management noted that performance in the US market had not been in line with expectations and various measures have been undertaken, including changing the management there and adding more sales resource to ensure Mikron is involved in all relevant pitches.

Mikron Machining

The market environment remained challenging with revenue down 13.4% y-o-y after a 14.7% decline in H125. Order

intake showed signs of stabilising, down only 0.9% y-o-y, and management expects improved order intake in H226 from new applications. By end market, the contribution from consumer goods (mainly watches) dropped from 46% to 37% of revenue with most of the difference increasing the Other category. By geography, the increase in contribution from Europe from 23% to 27% was offset by a decrease from North America from 20% to 16%. The order backlog declined 32.9% y-o-y to CHF49.1m.

Mikron Tool

The Tool division saw 17.6% order growth and 12.6% revenue growth in H126. Revenue contribution by end market and geography was essentially unchanged year-on-year. This business has had a more stable performance over the last three half years, we believe because cutting tools need to be replaced more frequently due to wear and tear. The company also noted that it has benefited from new applications, new sales channels and the trend towards productivity optimisation by customers.

Exhibit 2: Mikron Automation revenue by end market

By Industry	H1 2024	H1 2025	H1 2026
Automotive	5%	1%	2%
Pharma/Medtech	92%	97%	97%
Writing	0%	0%	0%
Consumer Goods	0%	0%	0%
Others	3%	2%	1%

Source: Mikron

Exhibit 3: Mikron Machining revenue by end market

By Industry	H1 2024	H1 2025	H1 2026
Automotive	9%	13%	13%
Pharma/Medtech	2%	8%	8%
Writing	17%	18%	20%
Consumer Goods	46%	46%	37%
Others	26%	15%	22%

Source: Mikron

Exhibit 4: Mikron Tool revenue by end market

By Industry	H1 2024	H1 2025	H1 2026
Automotive	12%	10%	10%
Pharma/Medtech	7%	6%	6%
Writing	2%	5%	5%
Consumer Goods	5%	14%	13%
Others	74%	65%	66%

Source: Mikron

Geographical expansion

A new Mikron Tool facility in the US is expected to start operations in Q326 and a new legal entity for the Automation and Machining divisions was incorporated in India, supporting the company's ambitions to grow in both regions.

Partnership for dry powder inhaler manufacturing

In April, the company announced a partnership with 3P innovation, a manufacturer of automation systems for dry power inhalers (DPIs). This partnership has been formed to develop and deliver a fully integrated solution, made up of complementary technologies, for DPI blister strip production, filling and device assembly. The two companies have previously collaborated, but this agreement moves the relationship to a more formal footing. DPIs typically consist of a disc-shaped plastic inhaler within which a blister strip containing multiple doses of medication in powder form is coiled. We understand that 3P innovation would provide the automated system for producing the blister pack, which would then be fed into a Mikron system to assemble the final inhaler product. The company is hopeful that the first customer contract under this partnership could be signed by year-end.

Outlook

The company confirmed its FY26 guidance for sales of CHF340–380m and an operating margin of 7–10%. We maintain our forecasts.

Exhibit 5: Financial summary

CHF'm	2020	2021	2022	2023	2024	2025	2026e	2027e
Year end 30 June	Swiss GAAP	Swiss GAAP	Swiss GAAP	Swiss GAAP	Swiss GAAP	Swiss GAAP	Swiss GAAP	Swiss GAAP
INCOME STATEMENT								
Revenue	257.8	289.5	309.4	370.2	374.1	381.9	359.2	372.1
EBITDA	(8.7)	27.1	34.4	42.4	41.3	49.5	40.1	42.9
Normalised operating profit	(20.1)	18.0	25.8	33.4	31.9	39.5	29.9	32.5
Amortisation of acquired intangibles	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Exceptionals	(0.7)	(0.4)	0.7	1.8	(0.8)	(0.3)	0.0	0.0
Share-based payments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Reported operating profit	(20.8)	17.6	26.4	35.3	31.2	39.2	29.9	32.5
Net Interest	(2.3)	(0.9)	(0.8)	(1.3)	(0.2)	(1.6)	(0.7)	(0.7)
Joint ventures & associates (post tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Exceptionals	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Profit Before Tax (norm)	(22.4)	17.2	24.9	32.1	31.7	37.9	29.3	31.9
Profit Before Tax (reported)	(23.1)	16.7	25.6	34.0	31.0	37.6	29.3	31.9
Reported tax	1.0	0.3	(1.4)	(5.2)	(3.1)	(5.1)	(4.4)	(4.8)
Profit After Tax (norm)	(21.4)	17.5	23.6	27.2	28.6	32.7	24.9	27.1
Profit After Tax (reported)	(22.1)	17.0	24.2	28.8	27.9	32.5	24.9	27.1
Minority interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (normalised)	(21.4)	17.5	23.6	27.2	28.6	32.7	24.9	27.1
Net income (reported)	(22.1)	17.0	24.2	28.8	27.9	32.5	24.9	27.1
Basic average number of shares outstanding (m)	16	16	17	17	17	17	17	17
EPS - basic normalised (CHF)	(1.31)	1.06	1.43	1.64	1.72	1.96	1.49	1.62
EPS - normalised fully diluted (CHF)	(1.31)	1.06	1.43	1.64	1.72	1.96	1.49	1.62
EPS - basic reported (CHF)	(1.35)	1.04	1.47	1.73	1.68	1.95	1.49	1.62
Dividend (CHF)	0.00	0.24	0.40	0.50	0.50	0.60	0.50	0.54
Revenue growth (%)		12.3	6.9	19.6	1.0	2.1	(6.0)	3.6
EBITDA Margin (%)	(3.4)	9.4	11.1	11.5	11.1	12.9	11.2	11.5
Normalised Operating Margin (%)	(7.8)	6.2	8.3	9.0	8.5	10.3	8.3	8.7
BALANCE SHEET								
Fixed Assets	112.4	135.4	133.7	102.8	115.5	126.2	142.8	149.2
Intangible Assets	3.8	3.6	2.9	2.5	3.5	3.4	4.3	5.2
Tangible Assets	75.6	87.7	88.2	87.4	100.0	112.4	128.1	133.6
Investments & other	33.0	44.1	42.6	12.8	12.1	10.4	10.4	10.4
Current Assets	164.7	164.6	212.2	271.5	283.6	252.9	250.0	263.1
Stocks	56.1	53.4	64.0	81.5	73.5	67.9	63.9	66.2
Debtors	68.2	56.7	83.8	105.9	86.9	84.9	87.6	90.6
Cash & cash equivalents	38.4	54.1	29.2	34.0	113.3	65.1	63.4	71.2
Other	2.0	0.4	35.2	50.1	10.0	35.0	35.0	35.0
Current Liabilities	(115.6)	(114.2)	(143.3)	(157.0)	(161.4)	(127.9)	(126.9)	(127.6)
Creditors	(43.3)	(41.9)	(48.5)	(51.2)	(55.8)	(61.2)	(60.1)	(60.9)
Tax and social security	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short-term borrowings	(14.2)	(2.1)	(1.8)	(1.2)	(1.0)	(0.5)	(0.5)	(0.5)
Other	(58.1)	(70.2)	(92.9)	(104.6)	(104.6)	(66.3)	(66.3)	(66.3)
Long-Term Liabilities	(16.0)	(20.7)	(16.6)	(13.4)	(11.5)	(14.6)	(14.5)	(14.4)
Long-term borrowings	(10.1)	(5.6)	(3.8)	(2.6)	(2.1)	(1.6)	(1.5)	(1.4)
Other long-term liabilities	(5.9)	(15.1)	(12.8)	(10.8)	(9.5)	(13.0)	(13.0)	(13.0)
Net Assets	145.5	165.1	186.0	203.8	226.2	236.6	251.5	270.3
Minority interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Shareholders' equity	145.5	165.1	186.0	203.8	226.2	236.6	251.5	270.3
CASH FLOW								
Op Cash Flow before WC and tax	(8.7)	27.1	34.4	42.4	41.3	49.5	40.1	42.9
Working capital	21.2	24.5	(6.3)	(29.8)	32.7	(26.0)	0.3	(4.5)
Exceptional & other	0.4	1.7	3.2	3.1	0.0	0.6	0.0	0.0
Tax	(1.5)	(1.7)	(2.8)	(3.9)	(4.4)	(9.8)	(4.4)	(4.8)
Net operating cash flow	11.5	51.6	28.5	11.8	69.6	14.3	36.0	33.7
Capex	(15.3)	(20.4)	(11.3)	(9.4)	(21.3)	(25.7)	(26.8)	(16.8)
Acquisitions/disposals	4.3	0.7	0.3	28.5	(0.0)	0.5	0.0	0.0
Net interest	(2.7)	(1.2)	(0.9)	(0.4)	0.6	(1.4)	(0.5)	(0.5)
Equity financing	0.0	0.0	0.0	(1.5)	(0.7)	(0.4)	0.0	0.0
Dividends	0.0	0.0	(3.9)	(6.6)	(8.3)	(8.3)	(10.0)	(8.3)
Other	0.0	0.0	0.0	0.4	0.6	0.8	0.0	0.0
Net Cash Flow	(2.2)	30.7	12.6	22.7	40.6	(20.4)	(1.4)	8.1
Opening net debt/(cash)	(16.4)	(16.1)	(46.8)	(58.8)	(80.3)	(120.2)	(98.0)	(96.5)
FX	(0.4)	0.1	(0.5)	(1.3)	0.5	(2.1)	0.0	0.0
Other non-cash movements	0.3	(0.5)	(0.2)	0.0	(1.2)	0.3	(0.1)	(0.2)
Closing net debt/(cash)	(16.1)	(46.8)	(58.8)	(80.3)	(120.2)	(98.0)	(96.5)	(104.4)

Source: Mikron, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by Mikron Holding and prepared and issued by Edison, in consideration of a fee payable by Mikron Holding. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.